Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: Insights from experimental heart failure

被引：3
作者：
Chen H.H. [1 ]
Cataliotti A. [1 ]
Burnett Jr. J.C. [1 ]
机构：
[1] Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905, Guggenheim 915
来源：
Current Hypertension Reports | 2001年 / 3卷 / Suppl 2期
基金：
美国国家卫生研究院;
关键词：
Natriuretic Peptide; Brain Natriuretic Peptide; Atrial Natriuretic Peptide; Fosinoprilat; Natriuretic Peptide System;
D O I：
10.1007/s11906-001-0102-y
中图分类号：
学科分类号：
摘要：
Vasopeptidase (VP) inhibitors are novel molecules that coinhibit neutral endopeptidase 24.11 (NEP), which degrades natriuretic peptides and angiotensin-converting enzyme (ACE). We review the biology of the natriuretic peptide system and a recent study of the role for the natriuretic peptide system in the mechanism of action of omapatrilat (the most clinically advanced VP inhibitor). This study compared the cardiorenal and humoral actions of omapatrilat with those of ACE inhibition. The actions of omapatrilat were further defined in the presence and absence of a natriuretic peptide receptor antagonist. This investigation provided insight into a unique new pharmacologic agent that has beneficial renal actions in experimental mild heart failure that exceed those seen with ACE inhibition alone and that are linked to the natriuretic peptide system. Copyright © 2001 by Current Science Inc.
引用
收藏
页码：s15 / s21
页数：6
相关论文
共 21 条
  • [1] Burnett Jr. J.C., Vasopeptidase inhibition: A new concept in blood pressure management, J Hypertens, 17, (1999)
  • [2] Robl J.A., Sun C.-Q., Stevenson J., Ryono D.E., Simpkins L.M., Cimarusti M.P., Dejneka T., Slusarchyk W.A., Chao S., Stratton L., Misra R.N., Bednarz M.S., Asaad M.M., Cheung H.S., Abboa-Offei B.E., Smith P.L., Mathers P.D., Fox M., Schaeffer T.R., Seymour A.A., Trippodo N.C., Dual metalloprotease inhibitors: Mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase, Journal of Medicinal Chemistry, 40, 11, pp. 1570-1577,
  • [3] Chen H.H., Lainchbury J.G., Matsuda Y., Harty G.J., Burnett Jr. J.C., Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure, Hypertension, 38, 2, pp. 187-191, (2001)
  • [4] Kenny A.J., Stephenson S.I., Role of endopeptidase 24.11 in the inactivation of atrial natriuretic peptide, FEBS Lett, 232, pp. 1-8, (1988)
  • [5] Burnett Jr. J.C., Kao P.C., Hu D.C., Atrial natriuretic peptide elevation in congestive heart failure in the human, Science, 231, 4742, pp. 1145-1147, (1986)
  • [6] Cavero P.G., Margulies K.B., Winaver J., Seymour A.A., Delaney N.G., Burnett Jr. J.C., Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure, Circulation, 82, 1, pp. 196-201, (1990)
  • [7] Margulies K.B., Perrella M.A., McKinley L.J., Et al., Angiotensin inhibition potentiates the renal response to neutral endopeptidase inhibition in dogs with congestive heart failure, J Clin Invest, 88, pp. 1636-1642, (1991)
  • [8] Chen H.H., Burnett Jr. J.C., Natriuretic peptides in the pathophysiology of congestive heart failure, Curr Cardiol Reports, 2, pp. 198-205, (2000)
  • [9] Borgeson D.D., Stevens T.L., Heublein D.M., Matsuda Y., Burnett J.C., Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: Functional cardiorenal responses to receptor antagonism, Clinical Science, 95, 2, pp. 195-202, (1998)
  • [10] Stevens T.L., Burnett Jr. J.C., Kinoshita M., Et al., A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction, J Clin Invest, 95, pp. 1101-1108, (1995)
123